Multiple Myeloma Clinical Trials in Pittsburgh, Pennsylvania

7 studies are recruiting for multiple myeloma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

2. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

4. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

   The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AHN West Penn Hospital, Pittsburgh, Pennsylvania

   Locations

   270 in total

   Run by

   Pfizer

   See if you can join NCT06152575 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

   The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 0023, Pittsburgh, Pennsylvania

   Locations

   19 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06121843 on ClinicalTrials.gov

6. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

   This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   212 in total

   Run by

   European Myeloma Network B.V.

   See if you can join NCT05243797 on ClinicalTrials.gov

7. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   104 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04988555 on ClinicalTrials.gov